GLUE: Monte Rosa Therapeutics, Inc.
Performance
GLUE -14.05%
Watchlist
Select an item
Summary
GLUE at a glance
GLUE returned -14.05% over the past year and -15.97% a year over five years. Its worst drop in that year was -61.52%, smaller than 11% of stocks on Redstone, and its Sharpe ratio of 0.15 beats 33% of stocks on Redstone. It pays no dividends.
Current Drawdown
-58.20%
Rolling Volatility
57.94%
Actions
Metrics
Risk Indicators
Alpha1.81%
Beta1.03x
Sharpe0.15
Sortino0.25
Omega1.03
Calmar-0.23
Martin0.37
Profile
About GLUE
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $903M
- Listed
- Jun 2021
- Employees
- 173
- Headquarters
- Boston, MA
- Website
- monterosatx.com
Comparisons